Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
About the Research Project
Program
Award Type
Standard
Award Amount
$85,000
Active Dates
January 01, 2025 - December 31, 2026
Grant ID
CA2025002
Acknowledgement
Goals
Sleep disruptions impact males and females differently in later life and are a known risk factor for Alzheimer’s disease.
Unique and Innovative
We believe that the longitudinal methodologies that we are using that allow us to track whole brain phenotypes using magnetic resonance imaging is extremely novel. Further, sex as a biological variable is typically completely overlooked in the context of preclinical work, thus modelling female-specific risk factors for the disease may provide important knowledge that may allow us to move towards precision medicine approaches.
Foreseeable Benefits
There is an overwhelming need to improve our understanding of female health in the context of neurodegenerative disorders. Understanding how sleep disturbance acts as a risk factor for Alzheimer’s diease and how the impact of this biological phenomenon may impact brain health is critical to developing interventions that may act on this important part of daily life.
Grants
Related Grants
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
Evaluation of Centrally Infused Muscarinic Agonist Drugs in Primates
Active Dates
April 01, 1986 - March 31, 1987
Principal Investigator
Robert Harbaugh, MD
Evaluation of Centrally Infused Muscarinic Agonist Drugs in Primates
Active Dates
April 01, 1986 - March 31, 1987
Principal Investigator
Robert Harbaugh, MD
Alzheimer's Disease Research
Evaluation of Centrally Infused Muscarinic Agonist Drugs Primates
Active Dates
April 01, 1987 - March 31, 1989
Principal Investigator
Robert Harbaugh, MD
Evaluation of Centrally Infused Muscarinic Agonist Drugs Primates
Active Dates
April 01, 1987 - March 31, 1989
Principal Investigator
Robert Harbaugh, MD